Eli Lilly And Co vs Tapestry, Inc. — how do they compare? Eli Lilly And Co trades at $1,214.46 (market cap $1.08T), while Tapestry, Inc. trades at $153.57 (market cap $32.44B). The key difference: Eli Lilly And Co is far larger — about 33.3× Tapestry, Inc.'s market cap, and Tapestry, Inc. pays the higher dividend (1%). Which is the better fit depends on your goals.
| LLY | TPR | |
|---|---|---|
Market Cap | $1.08T | $32.44B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.24K | $164.78 |
52-Week Low | $639.43 | $95.69 |
Enterprise Value | $1.13T | $35.29B |
Dividend Yield | 0.57% | 1% |
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.
LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.
TPR trades at $153.17, down 7.05% over 24 hours, with a bullish technical signal from moving averages and strong analyst consensus. The company reported Q1 2026 EPS of $1.66, beating expectations of $1.30, and maintains robust profitability with a gross margin of 76.18% and ROE of 55.74%. Recent news highlights AI integration efforts and upcoming Q4 earnings on August 13, 2026.
Outlook is positive driven by earnings beats and brand momentum, but risks include high valuation multiples and debt levels. The consensus price target is $190.33, implying significant upside, supported by 75.61% buy ratings from analysts. Investors should monitor Q2 2026 earnings and debt management for sustained growth.
Trailing returns across standard periods
Latest headlines on both assets
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →